1YI0 Stock Chart & Stats
€0.28
€0.00(0.00%)
At close: 4:00 PM EDT
€0.28
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.28 - €0.38
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.43M
Enterprise Value-€4.20M
Total Cash (Recent Filing)€6.11M
Total Debt (Recent Filing)€134.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 13, 2026EPS Estimate
-2.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding1,620,982
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)3.25
Price to Sales (P/S)0.00
P/FCF Ratio-5.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.93Price Target Upside5230.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthening Oncology Intellectual PropertyThe new U.S. patent allowance strengthens protection for CAPTN-3’s modular multispecific antibody architecture and may improve the company’s negotiating position with development or licensing partners. Durable intellectual-property coverage can preserve pipeline differentiation while programs advance.
Differentiated Immuno-oncology PlatformPreclinical findings support a potentially differentiated approach to solid tumors by combining tumor-selective activation with T-cell and NK-cell engagement. If these characteristics translate clinically, the platform could address unmet need and create partnership or commercialization opportunities.
Very Low Financial LeverageMinimal debt reduces refinancing and solvency pressure while the company funds its clinical-stage pipeline. Although the balance sheet is affected by losses, the low-leverage structure avoids substantial interest obligations and leaves more flexibility for future financing or strategic capital allocation.
Bears Say
No Meaningful Commercial Revenue And Persistent LossesThe absence of meaningful revenue leaves the company dependent on research progress, partnerships, financing, or eventual product approval to build an economic base. Persistent and widening losses also show that current R&D spending is not yet supported by a stable commercial offset.
Ongoing Cash BurnNegative operating and free cash flow indicate that the business is not self-funding and must continue consuming capital to advance its programs. Burn-rate moderation is constructive, but sustained funding needs remain a durable constraint until revenue scales or losses narrow.
Limited Funding Runway Before Clinical ExecutionA runway only into mid-2027 may require additional financing or a strategic partnership as the company advances toward clinical testing. External capital needs can constrain development choices and may expose shareholders to issuance-related dilution or unfavorable funding terms.
Purple Biotech News
1YI0 FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was €0.28 and its highest was €0.38 in the past 12 months.
What is Purple Biotech’s market cap?
Purple Biotech’s market cap is €9.43M.
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Nov 13, 2026 which is in 39 days.
How were Purple Biotech’s earnings last quarter?
Purple Biotech released its earnings results on Aug 07, 2026. The company reported -€0.365 earnings per share for the quarter, beating the consensus estimate of -€0.873 by €0.508.
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate is -2.56.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,620,982 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Purple Biotech reported an EPS of -€0.365 in its last earnings report, beating expectations of -€0.873. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Purple Biotech?
Currently, no hedge funds are holding shares in DE:1YI0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
1YI0 Stock 12 Month Forecast
Average Price Target
€14.93
▲(5230.43% Upside)